The Relationship Between CTLA-4 (-318 C/T) Polymorphism and Urothelial Cancer Carcinogenesis in Japanese Patients.
-318 c/t polymorphism
ctla-4
immunoregulatory molecule
japanese
urothelial cancer
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
accepted:
28
10
2023
medline:
4
12
2023
pubmed:
4
12
2023
entrez:
4
12
2023
Statut:
epublish
Résumé
Background Urothelial cancer is one of the most common types of urinary system cancer and there are several factors that can influence its growth. One of the most prominent factors among these is genetics. The Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) gene is suspected to be a susceptibility gene in urothelial carcinoma. The aim of this study is to investigate polymorphism in the CTLA-4 gene (CTLA-4 -318 C/T) and whether it is associated with urothelial cancer. Methods The study population consisted of 253 cases and 272 controls. In this case-control study, DNA was extracted from peripheral blood cells, and the CTLA-4 -318C/T genotypes were detected using polymerase chain reaction-restriction fragment length polymorphism. Results C/T (adjusted OR (aOR) 3.37; 95%CI: 1.98-5.74) genotype, C/T + T/T (aOR 3.25; 95%CI: 1.96-5.39) genotype, and T allele (aOR 2.94 95%CI: 1.87-4.62) all indicated they are significant risk factors for urothelial cancer, with the effects of polymorphism being higher in the nonsmoker group than in the smoker group. Furthermore, the association between polymorphism and urothelial cancer carcinogenesis was similar among men and women. Conclusions This is the first study examining the association between CTLA-4 -318C/T polymorphism and urothelial carcinoma in Japanese patients. A significant association between CTLA-4 -318C/T polymorphism and urothelial cancer among Japanese patients was detected in this study. This supports the development of research on polymorphisms in urothelial cancer and is an important root of immunoreactions in cancer. We believe this study will be beneficial to clarify the relationship between CTLA-4 polymorphism and urothelial cancer.
Identifiants
pubmed: 38046481
doi: 10.7759/cureus.48068
pmc: PMC10689122
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e48068Informations de copyright
Copyright © 2023, Damayanti et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Rev Cancer. 2003 Oct;3(10):733-44
pubmed: 14570033
Dis Markers. 2020 Dec 1;2020:8143158
pubmed: 33335608
Clin Cancer Res. 2012 Jun 15;18(12):3377-86
pubmed: 22553347
World J Urol. 2011 Aug;29(4):457-63
pubmed: 21656173
Nat Immunol. 2002 Jul;3(7):611-8
pubmed: 12087419
Am J Hum Genet. 1988 Jan;42(1):89-95
pubmed: 3337114
J Clin Oncol. 2006 Jul 20;24(21):3483-9
pubmed: 16849765
Eur Urol. 2013 Jun;63(6):1082-90
pubmed: 22743166
Gynecol Oncol. 2010 Oct;119(1):136-9
pubmed: 20615526
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936
Clin Cancer Res. 1999 Jan;5(1):129-34
pubmed: 9918210
Cancer Res. 2009 Aug 1;69(15):6158-63
pubmed: 19622768
Genes Immun. 2001 May;2(3):145-52
pubmed: 11426323
Hum Immunol. 2010 Feb;71(2):195-200
pubmed: 19913589
PLoS One. 2020 Sep 18;15(9):e0239426
pubmed: 32946523
Cell Physiol Biochem. 2018;47(2):721-734
pubmed: 29794465
Carcinogenesis. 2007 Jun;28(6):1237-40
pubmed: 17341658
Cancer Immunol Immunother. 2010 Feb;59(2):303-12
pubmed: 19672595
Cancer Res. 2000 May 1;60(9):2444-8
pubmed: 10811122
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Tumour Biol. 2014 Feb;35(2):1139-42
pubmed: 24014088
Nat Rev Cancer. 2014 Jun;14(6):419-29
pubmed: 24827506
Eur Urol. 2014 Apr;65(4):742-54
pubmed: 23810104
Mol Cancer Res. 2014 Jan;12(1):14-23
pubmed: 24398389
Cancer Lett. 2003 Jan 10;189(1):77-83
pubmed: 12445680
Lung Cancer. 2000 Dec;30(3):153-60
pubmed: 11137199
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Immunity. 1994 Aug;1(5):405-13
pubmed: 7882171
BMC Cancer. 2007 Sep 10;7:173
pubmed: 17825114
Ann Surg Oncol. 2005 Dec;12(12):1005-16
pubmed: 16283570
Hum Immunol. 2008 Mar;69(3):193-201
pubmed: 18396212
Genes Immun. 2002 Jun;3(4):233-4
pubmed: 12058260
Genes Immun. 2000 Feb;1(3):170-84
pubmed: 11196709
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
Int J Urol. 2017 Oct;24(10):730-734
pubmed: 28543959
Hum Immunol. 2007 Aug;68(8):698-704
pubmed: 17678726
Breast Cancer Res Treat. 2004 Jul;86(1):1-7
pubmed: 15218356
Diabetes Care. 2003 Mar;26(3):843-7
pubmed: 12610047
Annu Rev Immunol. 1996;14:233-58
pubmed: 8717514
Ann Neurol. 2005 Oct;58(4):644-8
pubmed: 16178018
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Cell. 2009 May 29;137(5):974-4.e1
pubmed: 19490900
BJU Int. 2014 Jul;114(1):56-61
pubmed: 24053463
Environ Health Prev Med. 2014 Jul;19(4):265-70
pubmed: 24803408
Gan To Kagaku Ryoho. 2020 Jun;47(6):941-946
pubmed: 32541172
Int J Cancer. 2009 Oct 15;125(8):1851-8
pubmed: 19585495